(Q53885340)

English

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

anti-retroviral agent

0 references

Anne-Geneviève Marcelin

12

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Dominique Costagliola

15

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Christine Katlama

16

object named as

Katlama C

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

author name string

Bossi P

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Peytavin G

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Ait-Mohand H

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Delaugerre C

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Ktorza N

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Paris L

6

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Bonmarchand M

7

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Cacace R

8

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

David DJ

9

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Simon A

10

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Lamotte C

11

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Calvez V

13

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Bricaire F

14

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

352-359

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Genotypic testing for human immunodeficiency virus type 1 drug resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Indinavir concentrations and antiviral effect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

High variability of plasma drug concentrations in dual protease inhibitor regimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00234.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2004.00234.X

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/15369510

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53885340&oldid=1267475394"